Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This trial is main evaluate the efficacy and safety of Pembrolizumab combined with Anlotinib
in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma
with CPS≥1